Interferon-λs: Special immunomodulatory agents and potential therapeutic targets

Journal of Innate Immunity

Volumn 5, Issue 3, 2013, Pages 209-218

  Zheng, Ya Wen ^a   Li, Hui ^a   Yu, Jin Pu ^a   Zhao, Hua ^a   Wang, Shizhen Emily ^b   Ren, Xiu Bao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Allergy; Asthma; Cancer; Immunomodulation; Interferon

Indexed keywords

B7 ANTIGEN; BETA INTERFERON; CHEMOKINE RECEPTOR CCR7; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERFERON; INTERFERON LAMBDA; INTERFERON LAMBDA 3; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 28A; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; JANUS KINASE; L SELECTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; IMMUNOMODULATING AGENT; INTERFERON RECEPTOR; LAMBDA INTERFERON;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ASTHMA; CANCER CELL; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENCEPHALOMYOCARDITIS VIRUS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ESOPHAGUS CARCINOMA; FOOD ALLERGY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; INFLUENZA A; KERATINOCYTE; LIGAND BINDING; LIVER CELL CARCINOMA; LUNG ALVEOLUS MACROPHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; RESPIRATORY EPITHELIUM; REVIEW; SIGNAL TRANSDUCTION; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH1 TH2 BALANCE; TH2 CELL; TUMOR IMMUNITY; UPREGULATION; VIRUS IMMUNITY; VIRUS INHIBITION; DRUG TARGETING; GENE EXPRESSION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC);

ANIMALS; ASTHMA; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TH2 CELLS;

EID: 84876785606     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000345365     Document Type: Review

References (99)

1. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77. (Pubitemid 36109115)
2. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63-68. (Pubitemid 36104710)
3. Zdanov A: Structural analysis of cytokines comprising the IL-10 family. Cytokine Growth Factor Rev 2010; 21:325-330.
4. Iversen MB, Paludan SR: Mechanisms of type III interferon expression. J Interferon Cytokine Res 2010; 30:573-578.
5. Ank N, West H, Paludan SR: IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 2006; 26: 373-379.
6. Kempuraj D, Donelan J, Frydas S, Iezzi T, Conti F, Boucher W, et al: Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities. Int J Immunopathol Pharmacol 2004; 17:103-106. (Pubitemid 39572165)
7. Li M, Liu X, Zhou Y, Su SB: Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86: 23-32.
8. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al: An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180: 2474-2485.
9. Pagliaccetti NE, Robek MD: Interferonlambda in the immune response to hepatitis B virus and hepatitis C virus. J Interferon Cytokine Res 2010; 30:585-590.
10. Kelly C, Klenerman P, Barnes E: Interferon lambdas: the next cytokine storm. Gut 2011; 60:1284-1293.
11. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, et al: Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007; 282: 7576-7581. (Pubitemid 47093699)
12. Donnelly R P, Kotenko SV: Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30:555-564.
13. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I: IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol 2007; 179:3434-3442.
14. Witte K, Witte E, Sabat R, Wolk K: IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010; 21:237-251.
15. Siegel R, Eskdale J, Gallagher G: Regulation of IFN-lambda1 promoter activity (IFN-lambda1/IL-29) in human airway epithelial cel ls. J Immunol 2011; 187: 5636-5644.
16. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, et al: Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805. (Pubitemid 39255927)
17. Hillyer P, Mane VP, Schramm LM, Puig M, Verthelyi D, Chen A, et al: Expression profiles of human interferon-alpha and interfer-on-lambda subtypes are ligand- and cell-dependent. Immunol Cell Biol 2012; 90:774-783.
18. He S, Li T, Chen H, Ma W, Yao Q, Yang H, et al: CD14+ cell-derived IL-29 modulates pro-inflammatory cytokine production in patients with allergic airway inflammation. Allergy 2011; 66:238-246.
19. He S, Zhang H, Chen H, Yang H, Huang T, Chen Y, et al: Expression and release of IL-29 by mast cells and modulation of mast cell behavior by IL-29. Allergy 2010; 65:1234-1241.
20. Wang J, Oberley-Deegan R, Wang S, Nikrad M, Funk CJ, Hartshorn KL, et al: Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda 1) in response to inf luenza A infection. J Immunol 2009; 182: 1296-1304.
21. Kotenko SV, Langer JA: Full house: 12 receptors for 27 cytokines. Int Immunopharmacol 2004; 4: 593-608. (Pubitemid 38559077)
22. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H: The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R 2) chain. J Leukoc Biol 2004; 76: 314 - 321. (Pubitemid 39006944)
23. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, et al: Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10:702-714.
24. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R: Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749-7758. (Pubitemid 47047861)
25. Kotenko SV: IFN-lambdas. Curr Opin Immunol 2011; 23: 583-590.
26. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC: Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269-32274. (Pubitemid 39014676)
27. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, et al: IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289:G960-G968. (Pubitemid 41532589)
28. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA: Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol 2011; 2011: 349575.
29. Sommereyns C, Paul S, Staeheli P, Michiels T: I F N-la mbda (I F N-la mbda) is expres sed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4:e1000017.
30. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al: IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci USA 2011; 108: 7944-7949.
31. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, et al: Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010; 84: 5670-5677.
32. Pulverer JE, Rand U, Lienenklaus S, Kugel D, Zietara N, Kochs G, et al: Temporal and spatial resolution of type I and III interferon responses in vivo. J Virol 2010; 84:8626-8638.
33. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63-68. (Pubitemid 36104710)
34. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R: Human interferonlambda3 is a potent member of the type III interferon family. Genes Immun 2009; 10: 125-131.
35. Liu BS, Janssen HL, Boonstra A: IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood 2011; 117:2385-2395.
36. Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, et al: Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One 2010; 5:e15200.
37. Mahlakoiv T, Ritz D, Mordstein M, Dediego ML, Enjuanes L, Muller MA, et al: Combined action of type I and type III interferon restricts initial replication of SARS-Coronavirus in the lung but fails to inhibit systemic virus spread. J Gen Virol 2012, E-pub ahead of print.
38. Pott J, Mahlakoiv T, Mordstein M, Duerr CU, Michiels T, Stockinger S, et al: IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci USA 2011; 108: 7944-7949.
39. Parczewski M, Bander D, Leszczyszyn-Pynka M, Urbanska A, Socha L, Boron-Kaczmarska A: IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients. AIDS Res Hum Retroviruses 2012, E-pub ahead of print.
40. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, et al: Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54: 859-865.
41. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al: Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51: 1904-1911.
42. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al: IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52:1888-1896.
43. Selvarajah S, Tobler LH, Simmons G, Busch MP: Host genetic basis for hepatitis C virus clearance: a role for blood collection centers. Curr Opin Hematol 2010; 17:550-557.
44. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna K V, Urban TJ, et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399 - 401.
45. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-1345, 1345.e1-e7.
46. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, et al: IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007; 178:5086-5098. (Pubitemid 46595292)
47. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T: Antitumor activity of IFN-lambda in murine tumor models. J Immunol 2006; 176:7686-7694. (Pubitemid 43849069)
48. Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, Spottl G, et al: Novel interferonlambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 2006; 344: 1334-1341.
49. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, et al: IF-Nalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008; 7:1109-1115.
50. Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, et al: Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferonlambda genes produced anti-tumour effects. Br J Cancer 2011; 105: 1302-1312.
51. Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, et al: Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anticancer agents. Eur J Cancer 2010; 46: 180 - 190.
52. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR: Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-4509.
53. Megjugorac NJ, Gallagher GE, Gallagher G: IL-4 enhances IFN-lambda1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra. Blood 2010; 115: 4185-4190.
54. Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, et al: Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008; 83:1181-1193. (Pubitemid 351960350)
55. Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, Fejer G, et al: Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med 2010; 207: 2703-2717.
56. Iversen MB, Ank N, Melchjorsen J, Paludan SR: Expression of type III interferon (IF N) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J Virol 2010; 84: 4579-4586.
57. Nordstrom I, Eriksson K: HHV-6B induces IFN-lambda1 responses in cord plasmacytoid dendritic cells through TLR9. PLoS One 2012; 7:e38683.
58. Megjugorac NJ, Gallagher GE, Gallagher G: Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J Leukoc Biol 2009; 86:1359-1363.
59. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, et al: Type III IFNs are produced by and stimulate human plasmacytoid dendritic cel ls. J Immunol 2012; 189: 2735-2745.
60. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, et al: Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8:254-261. (Pubitemid 46679436)
61. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, et al: IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 2011; 3:348-361.
62. Mennechet FJ, Uze G: Interferon-lambdatreated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006; 107:4417-4423. (Pubitemid 43801368)
63. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G: IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009; 113: 5829-5838.
64. Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G: Interferonlambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology 2008; 125:492-502.
65. Morrow MP, Yan J, Pankhong P, Shedlock DJ, Lewis MG, Talbott K, et al: IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther 2010; 18: 1714-1723.
66. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, et al: Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009; 113: 5868-5877.
67. Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, et al: Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 2010; 59: 1059-1071.
68. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, et al: IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007; 178:5086-5098. (Pubitemid 46595292)
69. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T: Antitumor activity of IFN-lambda in murine tumor models. J Immunol 2006; 176:7686-7694. (Pubitemid 43849069)
70. Pekarek V, Srinivas S, Eskdale J, Gallagher G: Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. Genes Immun 2007; 8:177-180. (Pubitemid 46390918)
71. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G: Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun 2007; 8:13-20. (Pubitemid 46164287)
72. Liu BS, Janssen HL, Boonstra A: Type I and III interferons enhance IL-10 receptor expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12. Eur J Immunol 2012; 42:2431-2440.
73. He SH, Chen X, Song CH, Liu ZQ, Zhou LF, Ma WJ, et al: Interferon-lambda mediates oral tolerance and inhibits antigen-specific, T-helper 2 cell-mediated inflammation in mouse intestine. Gastroenterology 2011; 141: 249-258, 258.e1-e2.
74. Guenterberg KD, Grignol VP, Raig ET, Zimmerer JM, Chan AN, Blaskovits FM, et al: Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis. Mol Cancer Ther 2010; 9: 510-520.
75. Sinha S, Guo Y, Thet S, Yuan D: IFN type I and type II independent enhancement of B cell TLR7 expression by natural killer cells. J Leukoc Biol 2012; 92: 713-722.
76. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
77. Hui X, Chen H, Zhang S, Ma X, Wang X, Huang B: Antitumor activities of recombinant human interferon (IFN)-lambda1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett 2011; 311: 141-151.
78. Fujie H, Tanaka T, Tagawa M, Kaijun N, Watanabe M, Suzuki T, et al: Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer. Cancer Sci 2011; 102: 1977-1990.
79. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, et al: Characterization of the mouse IFN-lambda ligandreceptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66:4468-4477.
80. Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, et al: Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 2010; 70:4539-4549.
81. Novak AJ, Grote DM, Ziesmer SC, Rajkumar V, Doyle SE, Ansell SM: A role for IFN-lambda1 in multiple myeloma B cell growth. Leukemia 2008; 22: 2240-2246.
82. Steen HC, Gamero AM: Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 2010; 30: 597-602.
83. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al: Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12:1023-1026. (Pubitemid 44353382)
84. Vareille M, Kieninger E, Alves MP, Kopf BS, Moller A, Geiser T, et al: Impaired type I and type III interferon induction and rhinovirus control in human cystic fibrosis airway epithelial cells. Thorax 2012; 67:517-525.
85. Gaudieri S, Lucas M, Lucas A, McKinnon E, Albloushi H, Rauch A, et al: Genetic variations in IL28B and allergic disease in children. PLoS One 2012; 7:e30607.
86. Herrick CA, Bottomly K: To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol 2003; 3: 405-412. (Pubitemid 37323200)
87. Edwards MR, Johnston SL: Interferon-lambda as a new approach for treatment of allergic asthma? EMBO Mol Med 2011; 3: 306-308.
88. Khaitov MR, Laza-Stanca V, Edwards MR, Walton RP, Rohde G, Contoli M, et al: Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cel ls. Allergy 2009; 64: 375-386.
89. Gallagher G, Megjugorac NJ, Yu RY, Eskdale J, Gallagher GE, Siegel R, et al: The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J Interferon Cytokine Res 2010; 30:603-615.
90. Moriwaki A, Matsumoto K, Matsunaga Y, Fukuyama S, Matsumoto T, Kan-o K, et al: IL-13 suppresses double-stranded RNA-induced IFN-lambda production in lung cells. Biochem Biophys Res Commun 2011; 404: 922-927.
91. Bullens DM, Decraene A, Dilissen E, Meyts I, De Boeck K, Dupont LJ, et al: Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy 2008; 38:1459-1467.
92. Wu Q, Yang Q, Lourenco E, Sun H, Zhang Y: Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity. Arthritis Res Ther 2011; 13: R88.
93. Lin SC, Kuo CC, Tsao JT, Lin LJ: Profiling the expression of interleukin (IL)-28 and IL-28 receptor alpha in systemic lupus erythematosus patients. Eur J Clin Invest 2012; 42:61-69.
94. Zahn S, Rehkamper C, Kummerer BM, Ferring-Schmidt S, Bieber T, Tuting T, et al: Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFN-lambda) in cutaneous lupus erythematosus. J Invest Dermatol 2011; 131: 133-140.
95. He SH, Song CH, Liu Z, Zhang H, Ma W, Zhou LF, et al: Eosinophil-derived interfer-on-lambda contributes to initiation of allergen-related inflammation in the intestine. Cy tok ine 2012; 58: 186-192.
96. Siebler J, Wirtz S, Weigmann B, Atreya I, Schmitt E, Kreft A, et al: IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. Gastroenterology 2007; 132: 358-371. (Pubitemid 46108741)
97. Belardelli F, Ferrantini M: Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 2002; 23: 201-208. (Pubitemid 34260936)
98. Rizza P, Moretti F, Belardelli F: Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010; 43: 204-209.
99. Pagliaccetti NE, Robek MD: Interferon-lambda in HCV infection and therapy. Viruses 2010; 2:1589-1602.